Abstract
Introduction
Kidney transplantation is the optimum treatment for most patients with end-stage renal disease. Immunosuppression remains the cornerstone of solid organ transplantation to prevent graft failure and increase graft survival. Basic maintenance immunosuppression for many years consisted of three types of drugs in combination: glucocorticosteroid (prednisolon), a purine antagonist (azathioprine or mycophenolate mofetil) and a calcineurin inhibitor (CNI, for example, cyclosporine or tacrolimus). [1] [2] [3] In 1983, FDA approved cyclosporine for mass use. Since then the new era of solid organ transplant begins. 4 Much of the success in organ transplantation has been credited to the use of cyclosporine. After its introduction, renal graft survival at 1 year increased from 64% to 78%. 5 But, despite the improvement in early graft function, long term kidney graft survival did not change significantly. [5] [6] [7] The chronic allograft nephropathy (CAN) and the potential toxicity of cyclosporine had prompted the development of tacrolimus, a drug which has a similar mode of action to cyclosporine. Tacrolimus was first used in clinical transplantation in 1989. 4 The studies produce some conflicting data regarding long term graft survival after use of cyclosporine or tacrolimus. Despite that the use of tacrolimus in kidney transplantation has considerably been increased.
Our aim of this study was to share our experience of the two CNIs at transplant unit of BIRDEM General Hospital.
Methods
This retrospective study was conducted in transplant unit of BIRDEM General Hospital. Data were collected in a preformed questionnaire from the hospital records with the permission from the Director General of the Institute. A total of 111 patients who had undergone live related donor kidney transplantation in BIRDEM from November 2004 to September 2014 were included in this study. They were divided into 2 groups, group 1 consisted of patients who received cyclosporine and group 2 consisted of those who received tacrolimus. We retrospectively evaluated patients' clinical and laboratory findings.
Results
Total patients were 111, 50 were in group I (who received cyclosporine) and 61 were in group 2 (who received tacrolimus). The base-line characteristics of the patients are given in table I. The immediate findings after transplantation were more in favor of patients on tacrolimus. The incidence of acute allograft rejection was significant (p=0.014) in group 1 and new onset of diabetes was significantly more (p=0.025) in group 2. During discharge from hospital after kidney transplantation, there was no significant difference in serum creatinine (p=0.258) of these two groups but, mean time for normalization of serum creatinine (p= 0.001) and mean duration of hospital stay (p= 0.005) were significantly less in group 2 (table II) .
Tacrolimus use was started in our center as maintenance immunosuppressive in October 2009. So, data of five years' graft survival was not available for them. There was no significant change in graft survival at one-year (p=0.308) and three-year (p=0.441) between the two groups of patients (table III) . 11 and so as Vincenti F et al. 12 in 1996.
The introduction of more potent immunosuppressive agents over decades has resulted in a progressive improvement in one-year graft survival rates after renal transplantation. While long-term graft survival has followed a similar trend, the number of functioning grafts continues to decline at an annual rate of 3-5% after the ûrst year post-transplantation. 13, 14 Since tacrolimus immunosuppression in renal transplantation is associated with a lower incidence of acute rejection, a more favourable cardiovascular risk proûle and better renal function than cyclosporine, it was anticipated that tacrolimus may improve long-term kidney graft survival. 15, 16 As we have started using tacrolimus in October 2009, we could study upto three years graft survival between two groups of patients. As in others we also found that overall graft survival was almost similar at one-year and three-years between the groups. But the immediate posttransplant recovery period was more favorable in patients receiving tacrolimus. Acute allograft rejection was noted only in patients with cyclosporine. Incidence of new onset diabetes was significant among tacrolimus users.
The patient pool was not so large and there is still scope to assess further long-term graft survival of these patients.
One of the CNIs, cyclosporine, had started a new era in transplant medicine by dramatic improvement in early graft survival after its launch. Tacrolimus is getting it further ahead which is also evident in our study. 
